eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases
Alkaptonuria: Follow-up
Updated: Apr 27, 2009
Follow-up
Further Inpatient Care
- If treatment for alkaptonuria is successful, the patient does not need to be admitted.
Further Outpatient Care
- Carefully monitor diet with periodic measurement of plasma amino acid levels to avoid phenylalanine deficiency.
Inpatient & Outpatient Medications
- Medications are not needed, although large doses of supplemental vitamin C may be beneficial.
Transfer
- Transfer is not required if appropriate outpatient consultation and follow-up are obtained.
Deterrence/Prevention
- High-protein diets should be avoided.
- No exercise restriction is necessary in the absence of cardiovascular disease.
Complications
- Calcification of the ear cartilage
- Calcified lumbar discs
- Severe arthritis
- Ankylosis
- Aortic or mitral valvulitis
Prognosis
- Life expectancy is normal.
- Risk of myocardial infarction later in life is increased.
Patient Education
- Family members should be referred for genetic counseling.
- The need for rigorous follow-up with a biochemical geneticist should be emphasized.
- For excellent patient education resources, visit eMedicine's Arthritis Center.
Miscellaneous
Medicolegal Pitfalls
- Patients with alkaptonuria have been misdiagnosed with acute intermittent porphyria.
Special Concerns
- Many affected individuals are asymptomatic. Therefore, all siblings of a newly diagnosed patient should be biochemically screened.
- Patients treated with dietary phenylalanine and tyrosine restrictions must be biochemically monitored.
More on Alkaptonuria |
| Overview: Alkaptonuria |
| Differential Diagnoses & Workup: Alkaptonuria |
| Treatment & Medication: Alkaptonuria |
Follow-up: Alkaptonuria |
| Multimedia: Alkaptonuria |
| References |
| « Previous Page | Next Page » |
References
Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J Biol Med. Jul-Aug 2002;75(4):221-31. [Medline].
Oexie K, Engel K, Tinschert S, et al. Three-generational alkaptonuria in a non-consanguineous family. J Inherit Metab Dis. Dec/2008;Epub:Epub.
US Preventive Services Task Force. Screening for phenylketonuria (PKU): US Preventive Services Task Force Reaffirmation recommendation. Ann Fam Med. Mar-Apr 2008;6(2):166. [Medline].
Peker E, Yonden Z, Sogut S. From darkening urine to early diagnosis of alkaptonuria. Indian J Dermatol Venereol Leprol. Nov-Dec 2008;74(6):700. [Medline].
de Haas V, Carbasius Weber EC, de Klerk JB, et al. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis. Dec 1998;21(8):791-8. [Medline].
Ffolkes LV, Brull D, Krywawych S, Hayward M, Hughes SE. Aortic stenosis in cardiovascular ochronosis. J Clin Pathol. Jan 2007;60(1):92-3. [Medline].
Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. Nov 2004;2(4):209-15. [Medline].
Keller JM, Macaulay W, Nercessian OA, Jaffe IA. New developments in ochronosis: review of the literature. Rheumatol Int. Mar 2005;25(2):81-5. [Medline].
Levine HD, Parisi AF, Holdsworth DE, Cohn LH. Aortic valve replacement for ochronosis of the aortic valve. Chest. Oct 1978;74(4):466-7. [Medline].
Lorenzini S, Mannoni A, Selvi E. Alkaptonuria. N Engl J Med. Apr 3 2003;348(14):1408; author reply 1408. [Medline].
Mayatepek E, Kallas K, Anninos A, Muller E. Effects of ascorbic acid and low-protein diet in alkaptonuria. Eur J Pediatr. Oct 1998;157(10):867-8. [Medline].
O'Brien W, La Du BN, Bunim JJ. Biochemical, pathological and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: review of the world literature (1584-1962). Am J Med. 1963;34:813-38.
Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol. Nov 2006;33(11):2280-5. [Medline].
Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. Dec 26 2002;347(26):2111-21. [Medline].
Suwannarat P, O'Brien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism. Jun 2005;54(6):719-28. [Medline].
Vavuranakis M, Triantafillidi H, Stefanadis C, Toutouzas P. Aortic stenosis and coronary artery disease caused by alkaptonuria, a rare genetic metabolic syndrome. Cardiology. 1998;90(4):302-4. [Medline].
Watts RW, Watts RA. Alkaptonuria: a 60-yr follow-up. Rheumatology (Oxford). Feb 2007;46(2):358-9. [Medline].
Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res. Aug 1989;26(2):140-4. [Medline].
Further Reading
Keywords
alkaptonuria, ochronosis, alcaptonuria, homogentisuria, dark urine, inborn error of metabolism, IEM, Croonian lectures, abnormal intermediate, homogentisic acid oxidase, homogentisate, vitamin C, arthritis, osteoarthritis, rheumatoid arthritis, ankylosis, dark stained diapers, coronary artery disease, myocardial infarction, phenylketonuria, treatment, diagnosis, joint effusion, aortic valvulitis, mitral valvulitis
Follow-up: Alkaptonuria